Clinical trials: Vinorelbine
Breast Cancer
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating older women who have stage IV…
- Trial name
- NCT00022152
- Testing
- vinorelbine tartrate
- Where
- 18 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Triple Negative Breast Cancer
Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival.
- Trial name
- AZALEA (NCT06690840)
- Testing
- Atezolizumab in combination with Cyclophosphamide and Vinorelbine
- Where
- 5 sites in Italy
- Volunteers
- 45 people
- Sponsor
- European Institute of Oncology
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004093
- Testing
- carboplatin, Gemcitabine, paclitaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
Advanced Non-Small Cell Lung Cancer
Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
The purpose of this study is to explore if the combination of vinorelbine and gemcitabine is better than vinorelbine and carboplatin in the treatment of advanced non-small cell lung cancer, in terms of survival, quality of life…
- Trial name
- NCT00737867
- Testing
- Vinorelbine, Gemcitabine, Carboplatin
- Where
- 4 sites in Norway
- Volunteers
- 444 people
- Sponsor
- The Norwegian Lung Cancer Study Group
Non Small Cell Lung Cancer
GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
A sub-population of patients affected by non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) do not gain benefit from treatment with tyrosine-kinase inhibitors (TKIs).
- Trial name
- NCT02319577
- Testing
- oral vinorelbine, Gefitinib
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Metastatic Breast Cancer
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
The investigators hypothesize that the administration of Toripalimab (anti-PD-1 antibody, JS001) combined to metronomic Vinorelbine may be an interesting therapeutic option for female patients with HER2- metastatic breast cancer.
- Trial name
- NCT04389073
- Testing
- Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003902
- Testing
- capecitabine, vinorelbine tartrate
- Where
- Switzerland
- Volunteers
- 110 people
- Sponsor
- Swiss Cancer Institute